Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance
Metrics: PDF 1134 views | HTML 1756 views | ?
Min Young Lee1, Austin Yeon2, Muhammad Shahid2, Eunho Cho3, Vikram Sairam3, Robert Figlin4, Khae-Hwan Kim5 and Jayoung Kim2,3,4,5
1Institute for Systems Biology, Seattle, WA, USA
2Department of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
3University of California Los Angeles, Los Angeles, CA, USA
4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
5Department of Urology, Ga Cheon University College of Medicine, Incheon, South Korea
Jayoung Kim, email: Jayoung.Kim@cshs.org
Khae-Hwan Kim, email: email@example.com
Keywords: lipidomics; cisplatin resistance; bladder cancer
Received: October 06, 2017 Accepted: January 06, 2018 Published: January 13, 2018
Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC) remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant BC have an extremely poor prognosis. One possible approach that may provide insightful and valuable information regarding resistance mechanisms is looking into the lipid metabolism of BC cells. Metabolism of lipids is essential for cancer cells and is associated with the regulation of a variety of key cellular processes and functions. This study conducted a comparative lipidomic profiling of two isogenic human T24 bladder cancer cell lines, one of which is clinically characterized as cisplatin-sensitive (T24S) and the other as cisplatin-resistant (T24R). Immunohistochemistry analysis revealed that expression of cytosolic acetyl-CoA synthetase 2 (ACSS2) is positively correlated with aggressive BC. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) analysis profiled a total of 1,864 lipids and levels of differentially expressed lipids suspected of being associated with cisplatin resistance were determined. In addition, we found that ACSS2 inhibition greatly perturbed levels of metabolites, including CE(18:1), CE(22:6), TG(49:1), and TG(53:2). This study broadens our current knowledge on the links between cisplatin resistance and lipid metabolism in aggressive BC and suggests potential biomarkers for identifying higher-risk patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.